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The present paper intends to overview a wide range of natural–origin polymers with special focus on proteins and polysaccharides (the systems
more inspired on the extracellular matrix) that are being used in research, or might be potentially useful as carriers systems for active biomolecules
or as cell carriers with application in the tissue engineering field targeting several biological tissues. The combination of both applications into a
single material has proven to be very challenging though. The paper presents also some examples of commercially available natural–origin
polymers with applications in research or in clinical use in several applications. As it is recognized, this class of polymers is being widely used due
to their similarities with the extracellular matrix, high chemical versatility, typically good biological performance and inherent cellular interaction
and, also very significant, the cell or enzyme-controlled degradability. These biocharacteristics classify the natural–origin polymers as one of the
most attractive options to be used in the tissue engineering field and drug delivery applications.
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Tissue engineering is the promising therapeutic approach
that combines cells, biomaterials, and microenvironmental
factors to induce differentiation signals into surgically trans-
plantable formats and promote tissue repair and/or functional
restoration. Despite many advances, tissue engineers still face
significant challenges in repairing or replacing tissues that serve
predominantly biomechanical functions such as articular car-
tilage. One obstacle can be identified as the scaffolds play an
important role as the extracellular matrix but they are often
unable to create the exact/correct microenvironment during the
engineered tissue development to promote the accurate in vitro
tissue development. The emerging and promising next gener-
ation of engineered tissues is relying on producing scaffolds
with an informational function, e.g., material containing growth
factors sequence which facilitates cell attachment, proliferation
and differentiation that is far better than non-informational
polymers. The use of growth factors has been considered as a
way to manipulate not only the host healing response at the site
of injury to facilitate the tissue repair, but also to manipulate and
improve the in vitro tissue growth in order to produce more
biofunctional engineered tissues. Hence, the strategy is to
mimic matrix and provide the necessary information or sig-
naling for cell attachment, proliferation and differentiation to
meet the requirement of dynamic reciprocity for tissue engi-
neering. This justifies the importance of drug delivery in tissue
engineering applications.
Moreover, natural polymers perform a diverse set of func-
tions in their native setting. For example, polysaccharides
function in membranes and intracellular communication and
also as storage, and proteins function as structural materials and
catalysts [1]. The current trend is to mimic nature and what
better way than materials from nature to do it? Natural bio-
polymers illustrate, as an impressive example, how all the
properties displayed by biological materials and systems are
exclusively determined by the physical–chemical properties of
the monomers and their sequence. A well-defined molecular
structure can lead to a rich complexity of structure and function
on the mesoscale [2]. Here, competing interactions, structural
flexibility and functional properties are tailored by the suc-
cession of monomeric units taken from a rather limited set.
Because macromolecules bridge the span of nanometers up to
micrometers by virtue of their length and flexibility, they enable
a unique control of hierarchical organization and long-rangeinteractions. Regardless of the tissue/organ involved, there are
many concepts that can be extrapolated from nature and
therefore applicable in the tissue engineering field to repair/
regenerate the tissue/organ. In many cases, the matrices and
scaffolds would ideally be made of biodegradable polymers
whose properties closely resemble those of the extracellular
matrix (ECM), a soft, tough, and elastomeric proteinaceous
network that provides mechanical stability and structural
integrity to tissues and organs [3].
If the constantly evolving knowledge on how our body
works and the needs to achieve repair, there is the need to
congregate into a sole construct both structural support and drug
delivery properties. For the purpose of this review, cell encap-
sulation will be considered as a delivery system, as this is
believed to be a promising therapeutic approach. Encapsulation
physically isolates a cell mass from an outside environment and
aims to maintain normal cellular physiology within a desired
permeability barrier [4]. Encapsulation techniques are generally
classified as microencapsulation (involving small spherical
vehicles and conformal coated tissues) and macroencapsulation
(involving larger flat-sheet and hollow-fiber membranes) [4].
The encapsulated cells can then be cultured in vitro or trans-
planted in vivo, either to repopulate a defect site or to produce
growth factors or other molecules that will have an effect over
the targeted cell population. Within the latter, cells have been
transfected with genes of interest (including BMPs, among
others) to make them true cellular factories to produce and
deliver active growth factors.
2. Protein-origin polymers
2.1. Introduction
In this paper, the attention is focused in several protein-based
polymers that found application in research works for drug or
cell delivery within the tissue engineering field, namely col-
lagen, gelatin, silk fibroin, fibrin (fibrinogen) and other proteins
such elastin or soybean. These protein-based polymers and their
applications in the field are described in more detail in the
following sections.
Protein-based polymers have the advantage of mimicking
many features of extracellular matrix and thus have the potential
to direct the migration, growth and organization of cells during
tissue regeneration and wound healing and for stabilization of
encapsulated and transplanted cells. In a molecular perspective,
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20 distinct amino acids linked by amide (or peptide) bonds.
Amino acids are therefore the building blocks of polypeptides
and proteins, which consist of a central carbon linked to an
amine group, a carboxyl group, a hydrogen atom, and a side
chain (R groups). R groups can be classified as non-polar
groups, uncharged polar groups or charged polar groups, and
their distribution along the protein backbone renders proteins
with distinct characteristics.
One of the drawbacks of the natural–origin polymers is their
possible batch variation. One interesting strategy to overcome
this issue is the recombinant protein technologies where the
monodispersity and precisely defined properties of polymers as
well as the predictable placement of crosslinking groups,
binding moieties at specific sites along the polypeptide chain or
their programmable degradation rates makes them very at-
tractive and useful for drug delivery and tissue engineering [2].
One example is presented when describing the elastin like
polypeptides. Our attempt to mimic nature to create materials is
routinely accomplished with exceptional high yield and
efficiency by the cellular systems of protein biosynthesis. Pro-
tein biosynthesis is implemented with an absolute control of
the amino-acid sequence [2,5,6], from the first amino acid to
the last, with complete absence of randomness. Additionally,
the protein biosynthesis machinery is able to process and pro-
duce any amino-acid sequence stored in the elements of infor-
mation called genes, so its flexibility is absolute. If one controls
the information that genes deliver into the machinery, one
completely controls the biosynthesis process itself. The key
issue to retain is to use highly purified and defined polymers in
order to have the perfect control over the developed final
product.
2.2. Collagen
Collagen is regarded by many as an ideal scaffold or matrix
for tissue engineering as it is the major protein component of the
extracellular matrix, providing support to connective tissues
such as skin, tendons, bones, cartilage, blood vessels, and
ligaments [7–11]. In its native environment, collagen interacts
with cells in connective tissues and transduces essential signals
for the regulation of cell anchorage, migration, proliferation,
differentiation, and survival [12]. Twenty-seven types of
collagens have been identified to date, but collagen type I is
the most abundant and the most investigated for biomedical
applications. The different collagens are first synthesized as
large precursor molecules known as procollagens [13]. After
secretion of procollagen into the extracellular matrix, both C-
and N-propeptides are cleaved and the molecules then self-
assemble into fibrils (a detailed review can be found in
[12]). Fibril-forming collagen molecules used in tissue
engineering applications consist of three polypeptide chains of
glycine-X-Y (Gly-X-Y) amino acid repeats twined around one
another to form triple helices [14,15]. Collagen is defined by
high mechanical strength, good biocompatibility, low antige-
nicity and ability of being crosslinked, and tailored for its
mechanical, degradation and water-uptake properties. Collagenis mainly isolated from animal tissues, and an additional
concern has been raised about the safety of the collagen derived
from animal tissues, based on the potential for viral and prion
contamination. However, purification techniques using enzy-
matic treatments may be employed to eliminate the immuno-
genic telopeptides, the major cause of foreign body response
[16,17], as well as the development of recombinant and non-
recombinant human collagens as a replacement for animal
tissue-derived material. However, alternatives to animal origin
collagens – those produced by recombinant technologies – still
present a high cost. Additionally, collagen is hard to process and
the extent and rate of degradability is hard to control. For the
latter, several factors have an impact on degradability of col-
lagen, for instance, the penetration of cells into the structure
causes contraction, as well as the fact that, besides collagenase
and gelatinase, several other non-specific proteinases are able to
digest collagen [18]. Crosslinking is necessary in order to tailor
the degradation of collagen and this has obviously to have into
account the application, as fluid movement, pressure and nature
of the tissue where the material is implanted contribute to a
faster degradation rate. In addition to the difficulties in pro-
cessability, the sterilization of collagen is also a problem, as
nearly all sterilization methods incur some degree of alteration
of collagen [18].
Collagen has been widely applied in tissue engineering ap-
plications and in some extent in delivery systems in this field.
Table 1 intends to summarize some relevant applications re-
ported as research works.
Recently, a broad range of tissue engineering products based
on animal-sourced collagen scaffolds have been developed and
commercialized. For example, bilayered collagen gels seeded
with human fibroblasts in the lower part and human kera-
tinocytes in the upper layer have been used as the ‘dermal’
matrix of an artificial skin product are commercialized by Or-
ganogenesis in USA under the name of Apligraf® and was the
first bio-engineered skin to receive FDA approval in 1998.
Organogenesis has other collagen-based products currently
under development such as Revitix™ (topical cosmetic pro-
duct), VCTO1™ (bilayered bio-engineered skin) or Forta-
Derm™ Antimicrobial (anti-microbial wound dressing).
inFUSE® Bone Graft are collagen sponges have been used
as an osteoconductive carrier of bone morphogenetic protein
(BMP-2) for spinal fusion marketed by Medtronic Sofamor
Danek in USA. Collagen sponges have been use also for the
treatment of long bone fractures [12]. Collagraft® commercial-
ized by Angiotech Pharmaceuticals, Inc. in Canada is a mixture
of porous hydroxylapatite and tricalcium phosphate and animal-
derived collagen I, has been used clinically for the treatment of
long bone fractures for more than a decade. Healos® Bone Graft
Replacement marketed by DePuy Orthopaedics in USA is an
osteoconductive matrix constructed of crosslinked collagen
fibers that are fully coated with hydroxylapatite and has been
approved recently for clinical use as a bone graft substitute
in spinal fusions [12] and Biomend® is a collagen membrane
conventionally used in the regeneration of periodontal tissue
and is a registered trademark of Integra LifeSciences Corp.
in USA [36].
Table 1
Collagen-based matrices/scaffolds for drug, cell and gene delivery used in different tissue engineering applications
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule Encapsulated/seeded cell type
(source)
Animal model References
Collagen/hydroxylapatite Bone NGF – Calvaria defects [19]
Collagen sponge Cartilage bFGF Chondrocytes Nude mice subcutaneous
implantation
[20]
Collagen gel Bone/cartilage BMP-2 gene Bone marrow stromal cells Mouse femoral muscle [21]
Collagen gel Skin PDGF-A gene – Rabbit dermal ulcer [22]
PDGF-B gene Swine dermal wound
Collagen gel Vascularization VEGF – Chorioallantoic membrane [23]
Collagen/heparan
sulfate matrix
Vascularization bFGF – Rat [24]
Collagen gel with
gelatin microspheres
Adipose FGF-2 – Mouse groin [25]
Collagen–agarose beads Not defined – Adults mesenchymal stem cells – [26]







Bone – Bone marrow-derived




Intervertebral disc – Human intervertebral disc cells – [29,30]
Collagen sponge Tooth – Porcine third molar cells Omentum of
immunocompromised rats
[31]
Collagen sponge Cartilage – Chondrocytes (autologous) Sheep chondral defects [32]
Collagen membrane Cartilage – Chondrocytes Medial femoral condyle of
New Zealand rabbits
[33]
Collagen sponge Adipose – Preadipocytes (human) Nude mice subcutaneous
implantation
[34]
Collagen–GAG scaffold Cardiovascular – Bone marrow-derived mesenchymal
stem cells
Rat myocardial infarction [35]
Collagen scaffold (fleece) Genito-urinary tract – Smooth muscle cells (human) Nude mice subcutaneous
implantation
[36]
Collagen vitrigel Renal glomerular tissue – Glomerular mesangial cells,
Epithelial cells
– [37]
Abbreviations: NGF: nerve growth factor; bFGF: basic fibroblast growth factor; BMP-2: bone morphogenetic protein-2; PDGF: platelet-derived growth factor; VEGF:
vascular endothelial growth factor; FGF-2: fibroblast growth factor-2; GAG: glycosaminoglycans.
Compiled from references [19–37].
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Gelatin is a natural polymer that is derived from collagen,
and is commonly used for pharmaceutical and medical
applications because of its biodegradability and biocompatibil-
ity in physiological environments as reviewed by Tabata and
Mikos [38,39]. These characteristics have contributed to gela-
tin's safety as a component in drug formulations or as a sealant
for vascular prostheses [40]. Moreover, gelatin has relatively
low antigenicity because of being denatured in contrast to
collagen which is known to have antigenicity due to its animal
origin. Gelatin contains a large number of glycine, proline and
4-hydroxyproline residues.
Gelatin is a denatured protein obtained by acid and alkaline
processing of collagen. As a result, two different types of gelatin
can be produced depending on the method in which collagen is
pre-treated, prior to the extraction process [40]. This pre-treat-
ment affects also the electrical nature of collagen, producing
gelatin with different isoelectric points. The alkaline process
targets the amide groups of asparagine and glutamine and hy-
drolyses them into carboxyl groups, thus converting many of
these residues to aspartate and glutamate. In contrast, acidic pre-
treatment does little to affect the amide groups present. Theresult is that gelatin processed with an alkaline pre-treatment is
electrically different from acidic-processed gelatin. This is due
to hydrolysis of amide groups of collagen yields gelatin with a
higher density of carboxyl groups present in the alkaline pro-
cessed gelatin rendering it negatively charge and lowering its
isoelectric point [38]. In contrast, the electrostatic nature of
collagen is hardly modified through the acid process because of
a less invasive reaction to amide groups of collagen. As a result,
the isoelectric point of gelatin that is obtained with the acid
process will remain similar to that of collagen [39]. By utilizing
this technique, manufacturers now offer gelatin in a variety of
isoelectric point values, being the most used the basic gelatin
with an isoelectric point of 9.0 and the acidic gelatin with an
isoelectric point of 5.0.
It is well accepted that a positively or negatively charged
polyelectrolyte electrostatically interacts with an oppositely
charged molecule to form a polyion complex [38]. The differ-
ent processing conditions of gelatin allows for flexibility in
terms of enabling polyion complexation of a gelatin carrier with
either positively or negatively charged biomolecules. It is theo-
retically possible for gelatin to form polyion complexes with
any type of charged biomolecules, although the strength of the
interaction depends on the type of biomolecules used. If the
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isoelectric point of 9.0 is preferable as a matrix, while acidic
gelatin with an isoelectric point of 5.0 should be applicable to
the control release of a basic protein. Both gelatins are insoluble
in water to prepare a hydrogel through chemical crosslinking,
for instance, with water-soluble carbodiimides and glutaralde-
hyde [39]. The gelatin hydrogels forming polyion complexes
with proteins will facilitate the release of biologically active
proteins. Generally, the release is controlled by matrix
degradation [39] and therefore the time period for biomolecule
release can be regulated by tailoring the hydrogel degradation.
The biodegradable hydrogel matrices are prepared by chemical
crosslinking of acidic or basic gelatin and are enzymatically
degraded in the body with time. The degradation is controllable
by changing the extent of crosslinking, which, in turn, produces
hydrogels with different water contents [41]. In addition, as
already referred, depending on the manufacturing method,
variations in the electrical and physical properties of gelatin-
based systems can be achieved. It is this flexibility in processing
that has allowed gelatin-based systems to find several
applications in fields ranging from tissue engineering to drug
delivery and gene therapy.
The properties of gelatin as a typical rigid-chain high
molecular weight compound are in many issues analogous to
those of rigid-chain synthetic polymers [42]. Gelatin exhibits
essentially the same common properties typical of polymeric
substances, which is not the case with native collagen. Thus, in
a similar way to linear-chain synthetic polymers, in aqueous
solutions gelatin macromolecules assume, at elevated tempera-
tures, the conformation of a statistical coil [42]. Under specific
conditions, such as temperature, solvent or pH, gelatin
macromolecules present sufficient flexibility to realize a variety
of conformations. This makes it possible to vary also all the
gelatin characteristics dependent on its molecular structure.
Besides, gelatin, similar to synthetic high polymers, shows a
rather wide molecular weight distribution [42]. Structural
diversity of gelatin chain units determines the specific features
of gelatin properties. Most synthetic polymers show no such
features that are typical of most biopolymers, such as the
presence of both acidic and basic functional groups in the
gelatin macromolecules.
Due to its promising properties, safety and mainly to the
possibility of polyion complexation, gelatin is been used in drug
delivery for tissue engineering applications targeting several
tissues as we try to summarize in Table 2. Targeted tissues
include bone, cartilage and skin, but others such as adipose
tissue have applied gelatin as carrier to delivery an active
biomolecule to improve the temporary cell functions. Due to its
easy processability and gelation properties, gelatin as been
manufactured in a range of shapes including sponges and
injectable hydrogels, but definitively the most used carriers are
gelatin microspheres which normally are incorporated in a
second scaffold such as a hydrogel.
One of the most common strategies using gelatin micro-
spheres is the encapsulation of biomolecules or cells in the
microspheres with further incorporation of those in a second
matrix. The group of Mikos [44–47,54,55] together with Tabatavast work with gelatin [49,50,53] has been commonly using this
strategy to incorporate a single biomolecule such as TGF-β1
[44,45], or in combination with IGF-1 for dual release [46] as
well as the encapsulation of marrow stromal osteoblasts in the
surface of the gelatin microspheres [54,55]. The results from
these studies show the efficacy and safety of using gelatin based
microspheres as carriers for tissue engineering applications.
Besides the incorporation of growth factors and cells, the
incorporation of cell adhesion proteins and peptides is also a
strategy to be implemented to achieve a successful tissue
engineering approach. Ito et al. [51] present a biodegradable
gelatin hydrogels prepared through crosslinking of gelatin with
transglutaminase (TGase) with fibronectin, vitronectin and
RGD peptides (RGDLLQ and RGDLLG) incorporated to be
applied as artificial skin or for bone and cartilage tissue
engineering. NIH/3T3 fibroblasts were then added into the
aqueous solution of gelatin to be part of the construct.
Vitronectin and fibronectin can bind with gelatin by the action
of TGase and as a cell adhesion factors it is expected to increase
the cell growth. In fact, this study has shown that the gelatin
matrices incorporating the cell adhesion factors such as
vitronectin, fibronectin and RGD peptides by the action of
TGase enhanced cell proliferation. Using gelatin carriers for cell
delivery as shown to be also a promising technology for tissue
engineering applications. Several examples include bovine and
human chondrocytes [47,56], mesenchymal stem cells [57,58]
and human preadipocytes [53] as described in Table 2. The
strategies range the co-implantation of loaded microspheres
[53] to the incorporation of the cells into porous scaffolds [57]
and, in general, the in vivo results shown the higher efficiency
of using gelatin carriers-based technology.
There are several commercially available gelatin based
carriers for drug delivery that are being applied in tissue
engineering applications [48,56,57]. The most commonly used
ones are Gelfoam® commercialized now by Pfizer in USA
(former Pharmacia and Upjohn) which is an absorbable gelatin
sponge being also available in the powder form by milling the
gelatin sponges. Gelfoam® is a sterile and workable surgical
sponge prepared from specially treated and purified gelatin
solution and it is used as a hemostatic device. Pfizer has also a
commercially available Gelfilm® that is an absorbable gelatin
film designed for use as an absorbable gelatin implant in
neurosurgery and thoracic and ocular surgery. Surgifoam® is
another commercially available porous, absorbable gelatin
disks. This product is distributed by Ethicon Inc. in USA.
CultiSpher-G® is another gelatin based product marketed by
Percell Biolytica AB in Sweden which is a macroporous gelatin
microcarrier beads used as microcarrier cell culture. CultiSpher-
S® is the same product with a different crosslinking procedure
conferring a higher thermal and mechanical stability.
2.4. Silk fibroin
Silk is generally defined as protein polymers that are spun
into fibers by some lepidoptera larvae such as silkworms,
spiders, scorpions, mites and flies [59]. Spider silk is an
intriguing biomaterial that is lightweight, extremely strong and
Table 2
Gelatin-based matrices/scaffolds for drug and cell delivery used in different tissue engineering applications
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule Encapsulated/seeded cell type
(source)
Animal model References











in a hydrogel injectable matrix
Cartilage TGF-β1 – – [44,45]
Gelatin microspheres encapsulated





in a hydrogel injectable matrix
Cartilage TGF-β1 Bovine chondrocytes – [47]
Porous gelatin disks (Surgifoam®) Cartilage TGF-β1 (medium) Human adipose-derived
adult stem cells
– [48]










Artificial skin RGD peptides
Gelatin microspheres incorporated
in collagen gel









in a collagen sponge




in an hydrogel matrix
Bone – Rat marrow stromal osteoblasts – [54,55]
Macroporous gelatin microcarriers
beads (CultiSpher G®)
Cartilage – Human nasal chondrocytes Nude mice
subcutaneous implantation
[56]
Porous gelatin sponge (Gelfoam®) Cartilage – Adult human mesenchymal
stem cells
Osteochondral defect in the
rabbit femoral condyle
[57]
Gelatin and chemically modified
hyaluronic acid injectable hydrogel





Abbreviations: bFGF: basic fibroblast growth factor; TGF-β1: transforming growth factor-β1; BMP-2: bone morphogenetic protein-2; RGD: Arg-Gly-Asp peptides;
FGF-2: fibroblast growth factor-2; IGF-I: insulin growth factor-1.
Compiled from references [25,38,43–58].
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best synthetic fibers produced by modern technology [60].
Spider silk is spun near ambient temperatures and pressures
using water as the solvent, which gives rise to an environmen-
tally safe, biodegradable material [60]. However, it is not
possible to maintain domesticated spiders to produce massive
amounts of silk. Therefore, the attention was turned to silk
fibroin, a mass-producible natural polymer produced by silk-
worms, commonly used as a textile fiber. In the medical field,
silk has long been used for surgical sutures [61].
The silkworm Bombyx mori produces silk to weave its
cocoon, and its major components are fibroin and sericin.
Fibroin is a fibrous protein constituting the core of silk, while
sericin is a glue-like protein surrounding fibroin. Fibroin is
composed of fibroin H-chain (FH), fibroin L-chain (FL), and
fibrohexamerin at a molar rate of 6:6:1 [62]. Silks are attractive
biomaterials for tissue engineering, because of their biocom-
patibility [59,63], slow degradability [64] and excellent
mechanical properties. Some examples are shown in Table 3.
Degradable silk is a mechanically robust biomaterial that offers
a wide range of mechanical and functional properties for
biomedical applications including drug delivery [65,66].Besides the applications that can be found in Table 3, a very
interesting approach is the one described by Hino and co-
workers [75] where the authors aimed to prepare a novel type of
bFGF delivery system using fibroin as a scaffold. They gene-
rated transgenic silkworms that bore a gene encoding FL fused
with bFGF (FL/bFGF). The transgenic silkworms spun cocoons
whose fibroin layers were composed of both inherent gene-
derived natural fibroin (nF) and the recombinant FL/bFGF,
r(FL/bFGF). When human umbilical vein endothelial cells
(HUVECs) were seeded in the scaffold, they were able to grow
in the refolded r(FL/bFGF)nF-containing culture media, show-
ing that bFGF in r(FL/bFGF) was biologically active [75]. r(FL/
bFGF)nF immobilized on a culture dish also supported
the growth of HUVECs in bFGF-free media, suggesting the
usefulness of r(FL/bFGF)nF as a new biomaterial for tissue
engineering [75].
2.5. Fibrin
Fibrin and fibrinogen have a well-established application in
research in tissue engineering due to their innate ability to
induce improved cellular interaction and subsequent scaffold
Table 3
Silk fibroin-based matrices/scaffolds for drug and cell delivery used in different tissue engineering applications
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule Encapsulated/seeded cell type
(source)
Animal model References
Silk fibroin fibre scaffolds Bone BMP-2 Bone marrow-derived mesenchymal
stem cells
– [67]
Silk fibroin hydrogel Bone – Osteoblasts Rabbit distal femurs [68]
Silk fibroin non-woven net Angiogenesis – Endothelial cells – [69,70]
Silk fibroin porous scaffolds Cartilage – Mesenchymal stem cells – [71]
Silk fibroin electrospun
fiber scaffolds
Wound dressing – Keratinocytes and fibroblasts – [72]
Silk fibroin/collagen scaffolds Liver – Hepatocytes – [73]
Silk fibroin multi-fiber matrix Anterior crucial ligament – Bone marrow-derived mesenchymal
stem cells
– [74]
Abbreviations: BMP-2: bone morphogenetic protein-2.
Compiled from references [67–74].
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to its biochemical characteristics, mainly in cellular interactions,
fibrin-based materials also found applications in the field of
drug delivery with special focus in cell delivery.
Fibrin is a protein matrix produced from fibrinogen, which
can be autologously harvested from the patient [76], providing
an immunocompatible carrier for delivery of active biomole-
cules, specially cells. Polymerized fibrin is a major component
of blood clots and plays a vital role in the subsequent wound
healing response [77]. In vivo, formation of fibrin clots is
initiated by vascular injury, which causes the release of the
enzyme thrombin, a serine protease that activates many con-
stituents of the coagulation cascade [78]. Thrombin cleaves
peptide fragments from the soluble plasma protein fibrinogen,
yielding insoluble fibrin peptides that aggregate to form fibrils
[79]. A fibrin meshwork is formed, which entraps platelets and
other blood-borne components to create a clot that is stabilized
through crosslinking by the transglutaminase Factor XIII
[79,80]. In addition, fibrin naturally contains sites for cell
binding, and therefore has been investigated as a substrate for
cell adhesion, spreading, migration and proliferation [81].
Fibrin glue is a biological adhesives also used in surgery
(abdominal, thoracic, vascular, oral, endoscopic) due to its
haemostatic, chemotactic and mitogenic properties [82]. Fibrin
glue mimics the last step of the in vivo coagulation cascade
through activation of fibrinogen by thrombin, resulting in a clot
of fibrin with adhesive properties [83]. Fibrinogen is converted
into a monomeric form of fibrin by thrombin which forms the
fibrin clot. Mechanisms of fibrin production and clot assembly
have been elucidated primarily from studies in which a specific
amount of thrombin is added to purified fibrinogen as clearly
described in [79]. The concentration of fibrinogen is 20–40
times higher in fibrin sealant products than in body fluid. The
formation of the fibrin clot and the physiological properties are
then enhanced. This concentration also determines the proper-
ties of the fibrin clot (adhesive strength, rate of formation,
network conformation, permeability and fiber diameter) and
modifications to concentrations can be made to allow the fibrin
glue to fit the application [82]. A number of variables other than
the concentration of thrombin and fibrinogen can also influencethe structure of a fibrin gel, including the local pH, ionic
strength, and concentrations of calcium [79]. The relative
influence of fibrinogen and thrombin concentration in the final
gel structure and properties when comparing with each other is
still not clear. There are works showing that fibrinogen con-
centration is more critical to the final properties [84,85] as well
as works showing that thrombin concentrations lead to more
modifications in the structure of the clot than modifications to
fibrinogen concentrations [78,83]. Extremely low concentra-
tions of thrombin (b1 nM, b0.1 U/mL) are sufficient to cleave
fibrino-peptides and catalyze fibrin polymerization [79]. These
low thrombin concentrations produce fibrin clots that are turbid
and composed of thick, loosely-woven fibrin strands. Higher
concentrations of thrombin produce fibrin clots that are
composed of relatively thinner, more tightly-packed fibrin
strands. There are a several works trying to stabilizing and
modulate the properties of the fibrin gels with thrombin in order
to get more stable gels [78,79]. However, this important fibrin
characteristic of increasing instability and solubility over time
in vitro and in vivo is due to fibrinolysis which could be an
advantage for in wound sealing or other surgical applications as
well as for cell and growth factor delivery. Fibrin provides a
material that can be rapidly invaded, remodeled and replaced by
cell-associated proteolytic activity [80]. Moreover, due to its
biomimetic and physical properties it is also widely used as a
cell carrier to many cell types, such as keratinocytes [86],
urothelium cells [86], tracheal epithelial cells [86], murine
embryonic stem cells [87] mesenchymal progenitor cells [88]
and also very used to encapsulate chondrocytes for cartilage
tissue engineering [89–91]. But rapid degradation can represent
a problem for use as a shape-specific scaffold in tissue engi-
neering, therefore optimizing fibrin composition is a funda-
mental approach to obtain a scaffold system providing optimal
shape stability and integrity for specific applications in tissue
engineering. In spite of this factor, fibrin as a carrier of active
biomolecules and particularly as support for cell delivery as
been applied to the tissue engineering field as presented in
Table 4. The table summarizes the polymer and carriers shape
used in the system, the aimed tissue engineering application, the
biologically active biomolecule to be delivered, the source of
Table 4
Fibrin-based matrices/scaffolds for drug and cell delivery described for different tissue engineering applications
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule Encapsulated/seeded cell type
(source)
Animal model References




Fibrin gel (Tisseel®) combined
with plotted PCL/TCP
Bone rhBMP-2 Human osteoblasts – [93]
Fibrin gel Bone ngl BMP-2 – Critical-size defects in
the rat calvarium and
inter-carpal fusion in dogs
[80]
Fibrin gel containing heparin-
conjugated nanospheres
Vascularization bFGF Human umbilical vein
endothelial cells
Mouse limb ischemia [94,95]






















Rat sciatic nerve defect [98–100]
Fibrin gel Intervertebral disc – Human intervertebral
disc cells
– [30]
Fibrin–collagen gel Cartilage – Embryonic chondrogenic cells – [91]
Fibrin gel Cartilage – Bovine articular chondrocytes – [89,90,101]
Fibrin gel in a PGA
non-woven mesh
Cartilage – Pig chondrocytes – [102]
Porous fibrin gel Cartilage – Human articular chondrocytes – [103]
Fibrin glue (Tisseel) combined
with plotted medical-grade PCL





Fibrin scaffold Spinal cord injury – Murine embryonic stem cells – [87]
Fibrin tubes (autologous) Vascularization – Outgrowth endothelial cells – [76]
Fibrin gel Vascularization – Rat aortic smooth muscle cells – [78]
Fibrin gel in a fiber-based scaffold Cardiovascular – Human venous
myofibroblasts
– [105]
Abbreviations: FGF-2: fibroblast growth factor-2; bFGF: basic fibroblast growth factor; NT-3: neurotrophin-3; NGF: nerve growth factor; β-NGF: beta-nerve growth
factor; VEGF: vascular endothelial growth factor; PCL: polycaprolactone; TCP: tricalcium phosphate; rhBMP-2: recombinant bone morphogenetic protein-2;
nglBMP-2: non-glycosylated form of bone morphogenetic protein-2; PGA: polyglycolic acid; TGF-β1: transforming growth factor-beta 1.
Compiled from references [30,76–78,80,81,87,89–105].
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type incorporated in the system in the last part of the table.
When applicable the used animal model is also referred.
One interesting work is presented by Aper et al. [76] where
autologous blood vessels are engineered from peripheral blood
sample. The objective is the development of a bioartificial
vascular graft by means of an autologous scaffold material
seeded with endothelial progenitor cells separated from the
peripheral blood of a single donor. With regard to a later clinical
application, the scaffold material should be generated easily
without the need for surgical procedure to harvest it from the
body of the later recipient [76].
Fibrinogen and thrombin from different sources including
human are commercially available in the usual chemical sup-
pliers and normally are used to produce the fibrin gel in research
works. Nevertheless, there is an already available industrially
produced homologous fibrin sealant. The most used one is
Tisseel VH® commercialized by Baxter, USA and consists of a
two-component fibrin biomatrix with highly concentrated
human fibrinogen. Moreover, it is possible also to producefibrin gel from a blood sample [76]. There are several com-
mercially available devices that allow for this. An example is
the CryoSeal® Fibrin Sealant System manufactured by
Thermogenesis in USA which enables the production of auto-
logous fibrin sealant components from a single unit of a pa-
tient's blood plasma in about 60 min. Another example is
Vivostat® System commercialized by Vivolution, Denmark
which is an automated system for the on-site preparation and
application of patient-derived fibrin sealant or platelet-rich
fibrin. There is a published study [106] which compares the
properties in different aspects concluding that there are clear
differences between the commercially available ways to obtain
fibrin gel.
2.6. Other protein-based polymers
There are other very interesting and attractive protein-origin
polymers namely elastin and soybean that have been applied in
some extent in the tissue engineering applications. We have
decided to include them just as a general overview due to the
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the tissue engineering field but justifying their use in tissue
engineering.
Elastin is the dominant extracellular matrix protein deposited
in the arterial wall and can contribute up to 50% of its dry weight.
The protein product of the elastin gene is synthesized by vascular
smooth muscle cells and secreted as a tropoelastin monomer that
is soluble, non-glycosylated and highly hydrophobic [107].
Elastin is the responsible component conferring elasticity, pre-
venting dynamic tissue creep by stretching under load and
recoiling to their original configurations after the load is re-
leased. In addition to the mechanical responsiveness, elastin is a
potent autocrine regulator of vascular smooth muscle cells
activity and this regulation is important for preventing fibro-
cellular pathology [6]. Given elastin importance in governing the
mechanical properties of native vessels and their role in vascular
smooth muscle cells activity, the development of processable
elastin-based biomaterials could advance the design of biofunc-
tional blood vessel replacements, in vascular tissue engineering
(where the main application is found) or achieving vasculariza-
tion in bone regeneration. Such elastin-based biomaterials may
not need to initially resemble the precise structural organization
of native elastin, but could serve as templates for cellular
remodeling and reorganization, being a critical issue in the
referred applications as reviewed by Patel et al. [6]. Neverthe-
less, the development of elastin-based biomaterials is still an
exploitable area for other application rather than vascular tissue
engineering. Examples of applications in this field are proposed
by Buttafoco et al. [108] where the addition of polyethylene
oxide and sodium chloride was necessary to spin continuous and
homogeneous elastin fibers by an electrospinning method. The
formation of a confluent multi-layer of smooth muscle cells,
growing on top of each nanofiber meshes was observed by
means of histology [108]. Other application is proposed by Lu
et al. [107] the attempt to create porous structures for cell
repopulation removing selectively matrix components from
decellularized porcine aorta to obtain two types of scaffolds,
namely elastin and collagen scaffolds. Fibroblasts were used for
cell culture and they infiltrated about 120 μm into elastin scaf-
folds and about 40 μm into collagen scaffolds after 4 weeks of
rotary cell culture. These results indicated that the developed
novel aortic elastin matrices have the potential to serve as scaf-
folds for cardiovascular tissue engineering. Moreover, Leach
et al. [109] propose a simple synthesis technique for creat-
ing elastin-based biomaterials. They present a versatile system
of two commercially available and water-soluble components:
α-elastin (a well-characterized elastin digest) and ethylene
glycol diglycidylether (a diepoxy crosslinker) to develop a pH-
dependent crosslinking scheme to yield insoluble α-elastin
biomaterials. Studies of vascular smooth muscle cells attach-
ment and proliferation were used to confirm the predicted cell
response to α-elastin substrates [109]. The results suggest that
crosslinked α-elastin could provide a platform for complex
composite materials with both mechanical and bioactive
properties that closely mimic native vascular tissue.
Recombinant protein technologies have allowed the synthe-
sis of well-defined elastin-derived polypeptides (ELPs), whichhave driven insightful structure–function studies of tropoelastin
(the soluble precursor of crosslinked elastin) and have gained
more attention. ELPs are artificial biopolymers composed of the
pentapeptide repeat Val-Pro-Gly-Xaa-Gly (VPGXG), which is
derived from the hydrophobic domain of tropoelastin. At low
temperatures, ELPs are soluble in aqueous solution, but as the
solution temperature is raised, they become insoluble and ag-
gregate at a critical temperature, termed the ‘inverse transition
temperature’ (Tt), a phenomenon similar to the lower critical
solution temperature transition [5]. This process is typically
reversible so that subsequent cooling of the solution below the
Tt results in the re-solubilization of the ELP. This transition has
become the key issue in the development of new peptide-based
polymers as molecular machines and materials. The basic
structure of ELPs is a repeating sequence originating in the
repeating sequences found in the mammalian elastic protein,
elastin [2]. Some of their main characteristics of these ELPs are
derived from the natural protein they are based on. For example,
the crosslinked matrices of these polymers retain most of the
striking mechanical properties of elastin, i.e. almost ideal elas-
ticity with Young's modulus, elongation at break, etc. in the
range of the natural elastin and outstanding resistance to fatigue
[5]. ELPs have found application in the drug delivery field due
to the ability to synthesize them with a precise molecular weight
and low poly-dispersity, their potential biocompatibility and
controlled degradation.
In the tissue engineering field, the biodegradation and bio-
compatibility of ELPs are suitable for preparing bulk implants
and/or injectables. These implants can hold cells, providing a
substrate for tissue engineering. In one approach, Betre et al.
[110] investigated the potential of a genetically engineered
ELPs to promote the chondrocytic differentiation of human
adipose derived adult stem cells without exogenous chondro-
genic supplements. The results demonstrate that ELPs can pro-
vide the appropriate physical and biochemical environment to
maintain chondrocyte differentiation and support cartilage ma-
trix synthesis in vitro and suggest the potential utility of ELPs to
serve as a scaffold for cartilage repair. Moreover, the study
suggests that ELPs can promote chondrogenesis for human
adipose derived adult stem cells in the absence of exogenous
TGF-β1 and dexamethasone, especially under low oxygen
tension conditions [110]. Finally the potential of ELPs to self-
assemble into nanostructures in response to environmental cues,
a nascent area of research, will lead to a host of new applications
of these recombinant polymers.
Soybean, from the most cultivated plant in the world, is
rich in proteins (40–50%), lipids (20–30%) and carbohydrates
(26–30%), and consequently the subject of extensive scientific
research [111]. The soybean (USA and UK) or soya bean (UK)
(from an annual plant, Glycine Max L. Merrill [112]) is a
species of legume native that can be processed into three kinds
of protein-rich products; soy flour, soy concentrate, and soy
isolate which varies in protein content. Isolated soy protein
(highly refined or purified form), the most concentrated source
of soy protein by definition contains 90% protein on a dry
weight basis, followed by soy concentrate (soybean without
the water-soluble carbohydrates) at 70% protein and soy flour
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on a dry weight basis. The major soy proteins (greater than
85%) are glycinin, or 11S, and β-conglycinin, or 7S, which
represent 34% and 27%, respectively, of the proteins occurring
in the isolate [111,113]. Soy protein is abundant, renewable,
inexpensive and biodegradable, making it an attractive source
of degradable materials for tissue engineering uses. Neverthe-
less, the application of soy-based polymers in this field is still
very narrow, especially if one considers application for growth
factor or cell delivery. The main field of soy application is by far
the food industry and more recently as environment-friendly
biodegradable ‘green’ alternatives for biolpolymers and com-
posites for use in various applications including computer cas-
ings and electronic chip packaging [112]. However, soy is also
expected to present a tailorable degradation profile [114] vary-
ing with the crosslinking degree which constitutes an advantage
for drug delivery systems design. Furthermore to improve soy
properties (namely mechanical, degradation, solubility and
hydrophilicity) it is common to mix with other polymers such as
dextran [115,116], chitosan [117], gelatin [118], carrageenan
[119], and starch [116,120]. The use of soy-based polymers for
drug delivery and tissue engineering applications is proposed by
the group of Reis et al. [117,121–123] where soy-based ther-
moplastics and membranes are described and characterized as
biomaterials and carriers for drug delivery applications.
3. Polysaccharidic polymers
3.1. Introduction
Polysaccharides are a class of biopolymers constituted by
simple sugar monomers [124]. The monomers (monosacchar-
ides) are linked together by O-glycosidic bonds that can be
made to any of the hydroxyl groups of a monosaccharide,
conferring polysaccharides the ability to form both linear and
branched polymers. Differences in the monosaccharide com-
position, chain shapes and molecular weight dictate their phys-
ical properties including solubility, gelation and surface
properties. These biological polymers can be obtained from
different sources: microbial, animal and vegetal [125]. Several
advantages can be derived from the use of these macromole-
cules. First of all, probably because of the chemical similarities
with heparin, polysaccharides show good hemocompatibility
properties. They are non-toxic, show interaction with living
cells and, with few exceptions, have low costs in comparison
with others biopolymers such as collagen [125,126]. These
polysaccharidic polymers have been widely proposed as scaf-
fold materials in tissue engineering applications as well as
carriers for drug delivery systems as described in more detail in
the following sections.
3.2. Chitosan
Chitosan is a cationic polymer obtained from chitin com-
prising copolymers of β(1→4)-glucosamine and N-acetyl-D-
glucosamine. Chitin is a natural polysaccharide found partic-
ularly in the shell of crustacean, cuticles of insects and cell wallsof fungi and is the second most abundant polymerized carbon
found in nature. Chitosan, the fully or partially deacetylated
form of chitin, due to its properties as attracted much attention
in the tissue engineering and drug delivery fields with a wide
variety of applications ranging from skin, bone, cartilage and
vascular grafts to substrates for mammalian cell culture. It has
been proved to be biologically renewable, biodegradable, bio-
compatible, non-antigenic, non-toxic and biofunctional [127].
The term chitosan is used to describe a series of polymers of
different degrees of deacetylation defined in terms of the per-
centage of primary amino groups in the polymer backbone and
average molecular weights. The degree of deacetylation of
typical commercial chitosan is usually between 70% and 95%,
and the molecular weight between 10 and 1000 kDa [128]. The
properties, biodegradability and biological role of chitosan are
dependent on the relative proportions of N-acetyl-D-glucos-
amine and D-glucosamine residues [129]. In preparing chitosan,
ground shells are deproteinated and demineralized by sequential
treatment with alkali and acid, after which the extracted chitin
is deacetylated to chitosan by alkaline hydrolysis at high tem-
perature. Production of chitosan from these sources is inex-
pensive, easy and can provide additional control over chitosan
final properties.
In addition, chitosan molecule has amino and hydroxyl
groups which can be modified chemically providing a high
chemical versatility and is metabolized by certain human en-
zymes, especially lysozyme being considered biodegradable.
Chitosan is also a bioadhesive material. The adhesive properties
of chitosan in a swollen state have been shown to persist well
during repeated contacts of chitosan and the substrate [128]
which implies that, in addition to the adhesion by hydration,
many other mechanisms, such as hydrogen bonding and ionic
interactions might also have be involved. Moreover, chitosan
exhibits a pH-sensitive behavior as a weak poly-base due to the
large quantities of amino groups on its chain. Chitosan dissolves
easily at low pH while it is insoluble at higher pH ranges. The
mechanism of pH-sensitive swelling involves the protonation of
amine groups of chitosan under low pH conditions. This prop-
erty has held chitosan to be widely investigated as a delivery
matrix. Crosslinking is often used to tailor chitosan-based ma-
terials properties. The most common crosslinkers used to cross-
link chitosan are dialdehydes such as glyoxal [130] and
glutaraldehyde [131]. The aldehyde groups form covalent
imine bonds with the amino groups of chitosan due to the
resonance established with adjacent double ethylinic bonds via
a Schiff reaction [128]. Dialdehydes allow the crosslinking to
happen by direct reaction in aqueous media and under mild
conditions. Moreover, dihaldehydes such as glutaraldehyde
stabilize the collagen structure, prevent tissue digestion by
enzymes or bacteria and reduce the antigenicity of the material
[132]. It also adds to retaining the biocompatibility of the
polymer. Natural crosslinkers like genipin [133] are gaining
wide acceptance for crosslinking chitosan.
Porous chitosan matrix may be suggested as a potential
candidate as a bone regenerative material due to its proper
biological and physical properties. Biological activity of chi-
tosan on bone regeneration has been demonstrated in many
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inducing rapid bone regeneration at initial stages. Bone for-
mation after implanting these matrices occurs over a long period
(several months or years) [127]. Additional functions for
chitosan materials are necessary to shorten bone forming period
and improve their efficacy. Incorporation of active biomolecules
such as growth factors has been used as a strategy which is
highly beneficial for obtaining improved bone regeneration.
Concerning cartilage engineering, chitosan is structurally
similar to glycosaminoglycans (GAGs) found in extracellular
matrices as in native articular cartilage and are very important in
playing a key role in modulating chondrocytes morphology,
differentiation and function. This characteristic together with
the ones previously described makes chitosan also an attractive
natural–origin polymer to engineered cartilage. In addition,
chitosan was found to enhance blood coagulation [136] accel-
erating wound healing [137,138], thus it can act as an ideal
wound dressing as it exhibits a positive charge, film-forming
capacity, mild gelation characteristics and a strong tissue-
adhesive property. Research work indicates that chitosan
enhances the functions of inflammatory cells such as polymor-
phonuclear leukocytes, macrophages and fibroblasts promoting
granulation and organization [136]. Therefore, chitosan can beTable 5
Chitosan-based matrices/scaffolds for drug, cell and gene delivery described for diff
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule
Chitosan–alginate fibers Not defined Dexamethasone, PDGF
Galactosylated chitosan coating Not defined EGF
Chitosan granules in a TCP/
chitosan hydrogel
Bone PDGF
Chitosan freeze-dried scaffolds Bone PDGF-BB
Chitosan/collagen scaffolds Periodontal bone TGF-β1 plasmid
Chitosan/coral scaffolds Periodontal bone PDGFB plasmid




Chitosan microspheres in chitosan
freeze-dried scaffolds
Cartilage TGF-β1










Chitosan hydrogels Vascularization FGF-2





Chitosan hydrogel Skin hEGF
Photocrosslinkable chitosan hydrogel Skin FGF-2
Particle aggregated chitosan scaffolds Bone/cartilage –
Abbreviations: TCP: tricalcium phosphate; PLGA: poly(lactide-co-glycolide); PD
transforming growth factor-β1; FGF-2: fibroblast growth factor-2; HUVEC: Human
Compiled from references [131,135,139–153].used for large open wounds [139]. A study showed that
chitosan-treated wounds were epithelized when compared with
wounds of the control group after the treatment [137,139].
Table 5 intends to summarize some relevant application of
chitosan-based materials in the tissue engineering field and drug
delivery aiming several tissues. The incorporation of a wide
range of bioactive molecule highlights the potential of this
natural origin to these applications, including gene delivery.
Some commercially available formats of chitosan include the
geniaBeads® CN commercialize by Genialab in Germany
which are hydrogel beads made from chitosan. Due to chitosan
properties in wound healing, a commercially available product
is HemCon® bandage from HemConMedical Technologies Inc.
in USA which is a chitosan bandage. This bandage can be
applied with pressure to a severe external wound and in several
minutes attracts blood cells (negatively charged surface) that
merge with chitosan forming a blood clot. The bleeding stops
and the bandage adhere tightly to the wound, so the person can
be moved without more bleeding. Chitosan has also been
marketed throughout the world as a component in non-medical
products, as a fat binder in cholesterol-lowering and slimming
formulations. It has been claimed that chitosan entraps lipids in




-BB – – [140]
Mouse hepatocytes – [141]
– Rat femur defect [142]













Rat calvarial defect [145]
Rabbit articular chondrocytes – [146]
Porcine articular chondrocytes – [147]








Mice neural stem cells – [152]







GF: platelet-derived growth factor; EGF: epidermal growth factor; TGF-β1:
umbilical vein endothelial cells.
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Starch is one of the most promising natural polymers because
of its inherent biodegradability, overwhelming abundance and
renewability. It is composed of a mixture of glycans that plants
synthesize and deposited in the chloroplasts as their principal
food reserve. Starch is stored as insoluble granules composed of
α-amylose (20–30%) and amylopectin (70–80%) [154]. α-
Amylose is a linear polymer of several thousands of glucose
residues linked by α(1→4) bonds. The α-glycosidic bonds of α-
amylose cause it to adopt an helical conformation (left-handed
helix) [154]. Amylopectin consists mainly of α(1→4)-linked
glucose residues but it is a branched molecule with α(1→6)
branch points every 24 to 30 glucose residues in average.
Amylopectin molecules contain up to 106 glucose residues,
making them some of the largest molecules in nature [154].
Starch by itself is extremely difficult to process and is brittle
when used without the addition of a plasticizer. In most appli-
cations, the semi-crystalline native starch granule structure is
either destroyed or reorganized, or both [155]. Water is the usual
plasticizer in starch processing, and the physical properties of
starch are greatly influenced by the amount of water present
[155]. Therefore, the use of other plasticizers, such as low
molecular weight alcohols, especially for the production of
thermoplastic starches, renders starch more processable [155].
Additionally, blending two or more chemically and physically
dissimilar natural polymers has shown potential to overcome
these difficulties. Over the years several materials have been
blended with starch to improve its processability, including, but
not restricted to, several synthetic polymers, such as polyeth-
ylene [156], polycaprolactone [157], polyethylene-co-vinyl
alcohol [158], poly(hydroxybutyrate-co-valerate) [159],
among others [160,161], or even other natural origin materials
such as other polysaccharides [162] and proteins [163]. Starch
has also been extensively modified by chemical methods such
as oxidation [164] and grafting of acryl reactive groups [165].
Due to its degradation by amylases [166], this constitutes
another strategy to tailor the degradation of starch-based mate-
rials [167,168]. A very important feature of most natural origin
materials when considered for biomedical applications is the
reaction of the host to degradation products (in the case ofTable 6
Starch-based matrices/scaffolds for drug and cell delivery described for different tis
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule
Starch-based porous scaffolds Bone Non-steroid anti-inflamma
Starch-based microparticles Bone Non-steroid anti-inflamma
Starch-based microparticles Bone Corticosteroids
Starch-based microparticles Bone PDGF
Starch-based microparticles Bone
Starch-based fiber mesh scaffolds Bone
Starch-based fiber mesh scaffolds Vascularization
Abbreviations: PDGF: platelet-derived growth factor.
Compiled from references [174,180–182,185–187].starch, degradation products are oligosaccharides that can be
readily metabolized to produce energy).
Starch has been extensively used for drug delivery applica-
tions, including cancer therapy [169], nasal administration of
insulin [170] among others [171,172]. Reis and co-workers
[173,174] have proposed starch-based materials (blends of
starch with different synthetic polymers, such as ethylene vinyl
alcohol, polylactic acid, cellulose acetate and polycaprolactone)
as materials with potential for biomedical applications. Since
then, others have studied the ability of these materials for
biomedical applications, namely as porous scaffolds [175,176].
The work of Reis and co-workers has been focused on a wide
range of biomedical applications, such as scaffolds for bone
tissue engineering applications [174,177], bone cements
[178,179] and as drug delivery systems [174,180–182]. These
materials have been shown to be biocompatible in vitro [183],
and to possess a good in vivo performance [184]. More recently,
these materials have been shown to permit the adhesion of
endothelial cells [185], an indicator of the ability of starch-based
fiber-based scaffolds to permit vascularization to occur. This
finding builds on the already proven potential of these materials
for tissue engineering applications.
Table 6 intends to summarize some relevant application of
starch-based materials in the tissue engineering field and drug
delivery.
3.4. Alginate
Alginate is one of the most studied and applied polysac-
charidic polymers in tissue engineering and drug delivery field.
They are abundant in nature and are found as structural com-
ponents of marine brown algae and as capsular polysac-
charides in some soil bacteria. Commercial alginates are
extracted from three species of brown algae. These include
Laminaria hyperborean, Ascophyllum nodosum, and Macro-
cystis pyrifera in which alginate comprises up to 40% of the dry
weight [128]. Bacterial alginates have also been isolated from
Azotobacter vinelandii and several Pseudomonas species
[128]. Alginates are naturally derived polysaccharide block
copolymers composed of regions of sequential β-D-mannuronic




tory agent – – [174]
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length of the M- and G-blocks and sequential distribution along
the polymer chain varies depending on the source of the algi-
nate. Alginates undergo reversible gelation in aqueous solution
under mild conditions through interaction with divalent-cations
such as Ca2+ that can cooperatively bind between the G-blocks
of adjacent alginate chains creating ionic inter-chain bridges.
This gentle property has led to their wide use as cell trans-
plantation vehicles to grow new tissues and as wound dressings.
Moreover, alginate as an anionic polymer with carboxyl end
groups is a good mucoadhesive agent [128]. However, alginate
hydrogels used in these applications have uncontrollable de-
gradation kinetics and gels dissolve in an uncontrollable manner
following the loss of divalent-cations releasing high and low
molecular weight alginate units. Attempts have been made to
covalently crosslink sodium alginate with gelatin and sodium
tetraborate [189] or with albumin [190].
The hydrogel is formed because blocks of guluronic residues
bind to cations resulting in a three dimensional network of
alginate fibers held together with ionic interactions. The model
that best describes this network is the “egg-box model” [191].
The resultant network is a function of the frequency and length
of contiguous guluronic acid residues as well as the concen-
tration and type of the cation [192]. The changes in frequency
and length of adjacent guluronic acid units, as well as, changes
in cation concentration can alter the number of alginate fibers
held together changing the overall strength of the network. In a
few words, alginates possessing a high guluronic acid content
develop stiffer, more porous gels which maintain their integrity
for longer periods of time. During cationic crosslinking, they do
not undergo excessive swelling and subsequent shrinking, thus
they better maintain their form [193]. On the other hand, algi-
nates rich in mannuronic acid residues develop softer, less
porous gels that tend to disintegrate with time. Consequently,
they are characterized by a high degree of swelling and shrink-
ing during cationic crosslinking [193].
The effects of alginate composition on the growth character-
istics and metabolic activity of encapsulated cells have yet to be
fully assessed. Nevertheless, the referred parameters that
defined the alginate network strength may be the majority
responsible for the differences in the growth characteristics of
cells encapsulated in different alginates as reported since by
Simpson and co-workers [193], as the network strength is a
conditional parameter to the nutrient diffusion and cell-to-cell
contact. The work of Yoon et al. [194] also reports the influence
of alginate concentration and cell concentration in the
expression of insulin-like growth factor-1 (IGF-1) of encapsu-
lated chondrocytes.
Alginate-based materials are pH-sensitive. Biomolecules
release from alginate-based materials in low pH solutions is
significantly reduced which could be advantageous in the de-
velopment of a delivery system. Theoretically, alginate shrinks
at low pH and the encapsulated drugs are not released. This pH-
dependent behavior of alginate is exploited to tailor release
profiles and in the development of ‘smart’ systems. However, at
higher pH alginate undergoes a rapid dissolution which may
result in burst release of protein drugs and subsequently theirdenaturation by proteolytic enzymes. Therefore, many mod-
ifications in the physicochemical properties are needed for the
prolonged controlled release of protein drugs [195,196].
Due to its biocharacteristics and the mild gelation process
conditions, alginate templates are by far one of the natural origin
polymers applied in tissue engineering applications even con-
sidering growth factor delivery or cell encapsulation, as Table 7
demonstrates. If one analyses the vast examples in the table,
cartilage tissue engineering arises as the major application
mainly to the need of the 3D culture of chondrocytes. Alginate
beads/hydrogels can be prepared by extruding/maintaining a
solution of sodium alginate containing the desired protein or
cells, as droplets/blocks, in to a divalent crosslinking solution
such as Ca2+, Sr2+, or Ba2+. Monovalent cations and Mg2+ ions
do not induce gelation [128]. Although alginate beads/
hydrogels can be prepared by simple and mild procedures,
this method has a major limitation that is the drug loss during
bead/hydrogel preparation, by leaching through the pores in the
beads/hydrogels.
One nature-inspired approach that has been attracting more
attention is the use of biological multi-protein supplements as
source of several growth factors to improve cell behavior. The
biochemical stimulus provided in the initial critical stages of
cell culture for engineered tissues may differ from that for single
growth factor delivery. One example of this potential approach
is given by Gaissmaier and co-workers [204] by using human
platelet supernatant. As it is known, platelets are a rich source of
many growth factors including transforming growth factor-β
and platelet-derived growth factor. However, the authors report
that in spite of the addition of human platelet supernatant
accelerate chondrocytes expansion can lead to their dedifferen-
tiation. Other reported approach is the use of platelet-rich
plasma isolated from autologous blood (porcine source) sug-
gesting that the cells remain phenotypically stable in the pre-
sence of platelet-rich plasma [205]. Another strategy is
proposed for angiogenic growth factors by using endothelial
cell growth supplement [209] as source for vascular endothelial
growth factor (VEGF), several endothelial cell growth factors
(ECGFs) and basic fibroblast growth factor (bFGF). The study
demonstrates that the controlled release of endothelial cell
growth supplement leads to a two-fold increase in neovascular-
ization at the material-tissue interface. However, the study does
not include any comparison with the effect of any single growth
factor.
For cartilage tissue engineering, periosteum can be use not
only as source for chondrogenic growth factors but also as
source for chondrogenic precursor cells as reported in the work
of Stevens and colleagues [188]. Besides these, other advantage
of periosteum over cell cultures for cartilage or osseous tissue
engineering include the fact that it can serve as a template for
directional evolution of tissue. The periosteum contains a source
of chondrogenic growth factors that if supplemented in vitro by
the morphogen TGF-β1 can drive the terminal differentiation of
the precursor cells into a chondrocyte phenotype [188]. The in
vitro culture of periosteal explants within the alginate hydrogel,
showed that after 6 weeks more than 50% of the total area of the
periosteal explants was composed of cartilage that was hyaline-
Table 7
Alginate-based matrices/scaffolds for drug and cell delivery described for different tissue engineering applications
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule Encapsulated/seeded cell type
(source)
Animal model References
Alginate–chitosan fibers Not defined Dexamethasone, PDGF-BB – – [140]
Alginate hydrogel Bone/cartilage BMP-2 gene Bone marrow stromal cells Mouse femoral muscle [21]
Alginate beads Cartilage BMP-2 Human articular chondrocytes – [197]
Alginate beads Cartilage IGF-1, TGF-β2 and FGF-2 Bovine articular chondrocytes – [198]
Alginate beads Cartilage rhOP-1 (medium) Bovine articular chondrocytes – [199]
Alginate hydrogel and film Cartilage FGF-2 and TGF-β (medium) Rabbit periostal explants – [188,200]
Alginate beads Cartilage BMP-2,4,5,6,7 Chondrocytes (transfected) Nude mice
subcutaneous implantation
[201]
Alginate beads Cartilage TGF-β – Rabbit knee
osteochondral defects
[202]





Alginate beads Cartilage Human platelet supernatant Human articular chondrocytes – [204]
Alginate beads Cartilage Porcine platelet-rich plasma Porcine articular chondrocytes – [205]
Alginate beads Vascularization bFGF, VEGF, EGF – Rat myocardial infarction [206]





Vascularization VEGF conditioned medium Human CCD-18Co fibroblast cells
and HDMECA
– [208]









BDNF – Rat sciatic nerve [210]
Alginate hydrogels with
RGD-containing peptides
Bone BMP-2 and TGF-β3 Rat bone marrow stromal cells Nude mice
subcutaneous implantation
[211]
Alginate hydrogel Intervertebral disc TGF-β1 Human intervertebral disc cells – [29,30,212]





Alginate hydrogel Cartilage Glucose (medium) Cattle articular chondrocytes – [214]
Alginate freeze-dried
sponges and combined with
hyaluronic acid





Cartilage – Bovine articular chondrocytes Nude mice
subcutaneous implantation
[216]
Alginate hydrogel Cartilage – Bovine articular chondrocytes – [101,194]
Alginate gel alone and
in PGA-PLA pads












Liver – Rat hepatocytes – [189]
Alginate beads Pancreas – Murine insulinoma βTC3 cells – [193]
Abbreviations: PDGF-BB: recombinant human platelet-derived growth factor-BB; BMP: bone morphogenetic protein; IGF-1: insulin growth factor; TGF-β:
transforming growth factor; FGF: fibroblast growth factor; rhOP-1: recombinant human osteogenic protein-1; EGF; epidermal growth factor; VEGF: vascular
endothelial growth factor; BDNF: brain derived neutrophic factor; CCD-18Co: normal colon fibroblast cells derived from human colon; HDMECA: adult human
dermal microvascular endothelial cells; PGA-PLA: co-polymer of polyglycolic acid-polylactic acid; Ethisorb210: non-woven fleece composed of a polyglycolic–
polylactic-copolymer punctually glued with polydioxanon; PP: polypropylene, PS: polysulfone.
Compiled from references [21,29,30,48,101,140,188,189,193,194,197–218].
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capsulated chondrocytes where constructs supported the in vitro
culture for a period of several weeks but did not form a hyaline-
like cartilaginous tissue [188].
Concerning the commercially available products, alginate
has been widely marketed as wound dressings. Examples are
Nu-Derm® commercialized by Johnson & Johnson in USA,
Curasorb® by Kendall or AlgiSite® by Smith & Nephew in
USA. Genialab in Germany is marketing geniaBeads® CA
which are hydrogel beads made from calcium alginate. The
hydrogel beads' size can be chosen from a wide range of 0.2 to3 mm to give them the desired properties regarding eye-appeal,
release properties, or technical demands in general. A more
tissue engineering driven product is commercialize by Articular
Engineering LCC in USA for research purposes that has a
variety of available products ranging engineered tissues, iso-
lated cells, native tissues and cryopreserved cells from cartilage,
synovium and intervertebral disc from both bovine or human
origin using alginate beads with the alginate-recovered-
chondrocyte or ARC™ method. A study was published on
further development in this technology using osteogenic
protein-1 [199].
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Hyaluronic acid is most frequently referred to as hyaluronan
due to the fact that it exists in vivo as a polyanion and not in the
protonated acid form [219]. Hyaluronan is a naturally occurring
non-sulfated glycosaminoglycan and a major macromolecular
component of the intercellular matrix of most connective tissues
such as cartilage, vitreous of the human eye, umbilical cord and
synovial fluid [219]. Hyaluronic acid is a linear polysaccharide
that consists of alternating disaccharide units of α-1,4-D-
glucuronic acid and β-1,3-N-acetyl-D-glucosamine, linked by
β(1→3) bonds [220]. Hyaluronan and its associated networks
have many physiological roles that include tissue and matrix
water regulation, structural and space-filling properties, lubri-
cation, and a number of macromolecular functions [219]. Es-
pecially for its enhanced viscoelastic properties, hyaluronan
works as a lubricant and shock absorber in synovial fluid [124].
Hyaluronan has been widely studied for drug delivery, for
dermal, nasal, pulmonary, parenteral, liposome-modified, im-
plantable delivery devices and for gene delivery (reviewed in
Liao et al. [219]). Hyaluronan for tissue engineering has been
focused on cartilage, bone and osteochondral applications, most
likely due to the fact that it is a major macromolecular compo-
nent of the extracellular matrix. The most relevant applications
are summarize in Table 8.
Commercially available hyaluronan is obtained from differ-
ent sources, mainly by extraction from umbilical cord, rooster
comb, synovial fluid, or vitreous humour. In addition, hyal-
uronic acid can be easily and controllably produced in large
scales through microbial fermentation, from strains of bacteria
such as Streptococci [219], enabling the scale-up of derived
products and avoiding the risk of animal-derived pathogens.
Hyaluronan is available for several applications, for lubrication
and mechanical support for the joints in osteoarthritis
(Hyalgan® and Hyalubrix® from Fidia in Italy; Artz® fromTable 8
Hyaluronan-based matrices/scaffolds for drug and cell delivery described for differe
Polymer(s)/carrier/
scaffold structure




Not defined Fibronectin NIH 3T
Hyaluronan–alginate scaffold Not defined bFGF –
Hyaluronate gel Bone/cartilage BMP-2 gene Bone m
Hyaluronic acid gel Vascularization bFGF –




Hyaluronic acid hydrogel Cartilage – Auricul
Hyaluronic acid (Hyaff®11)
non-woven mesh scaffold
Osteochondral – Bone m









Abbreviations: BMP-2: bone morphogenetic protein-2; bFGF: basic fibroblast grow
Compiled from references [21,34,221–230].Seikagaku Corporation in Japan) as a viscoelastic gel for
surgery and wound healing (Bionect® from CSC Pharmaceu-
tical in USA; Jossalind® from Hexal in Germany), for im-
plantation of artificial intraocular lens (Healon® from OVD
from Advanced Medical Optics in USA, Opegan R® from
Seikagaku in Japan, Opelead® from Shiseido in Japan,
Orthovisc® from Anika in USA) and as culture media for use
in in vitro fertilization (EmbryoGlue® from Vitrolife, USA)
[219]. Hyaff® commercialized by Fidia in Italy has been widely
used as a biomaterial for biomedical applications as described in
Table 8. From a chemical standpoint, Hyaff® is a benzyl ester of
hyaluronic acid and its main characteristics are that HYAFF®
maintains the biological characteristics of the natural molecule
from which1 it derives, the natural degradation of Hyaff®
releases hyaluronic acid, which is then degraded through well-
known metabolic pathways and that depending on the levels of
esterification (e.g. the percentage of carboxylic groups
interested by the esterification reaction), it is possible to obtain
polymers with different levels of hydrophobicity.
3.6. Chondroitin sulphate
Extracellular matrix components are valuable building
blocks for the preparation of biomaterials involved in tissue
engineering, especially if their biological, chemical and phys-
ical characteristics can be controlled. An example is chondroitin
sulfate, one of the most physiologically important glycosami-
noglycans. Glycosaminoglycans (GAGs) are found in the lubri-
cating fluid of the joints and as components of cartilage,
synovial fluid, bone, and heart valves. With the exception of
hyaluronan, these polysaccharides are covalently linked to a
protein core, thereby forming proteoglycans [231]. Biochar-
acteristics of GAGs include the binding and modulation of
growth factors and cytokines, the inhibition of proteases, and




3 fibroblasts – [221]
– [222]
arrow stromal cells Mouse femoral muscle [21]
Nude mice subcutaneous implantation [223]
Spinal cord injury [224]
ocytes Nude mice subcutaneous implantation [225]
ar chondrocytes Nude mice subcutaneous implantation [226]
arrow mesenchymal cells Rabbit osteochondral knee lesion [227]




cytes, keratinocytes – [230]
ocytes Nude mice subcutaneous implantation [34]
th factor.
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non-immunogenic and degrade to non-toxic oligosaccharides.
These characteristics together with their defined physical and
chemical characteristics make them very interesting materials
for tissue engineering. Due to its GAG nature, chondroitin
sulfate is an attractive natural–origin polymer applied essen-
tially in cartilage tissue engineering. Nevertheless, and due to its
biological properties (mainly the ability to interact with various
growth-active molecules), is often used in other tissue engi-
neering applications to valorize other polymers in order to
interact with cells and proteins improving cell behavior of the
developed materials.
Chondroitin sulfate consists of repeating disaccharide units
of D-glucuronic acid and N-acetyl galatosamine sulfated at
either 4- or 6-positions [233]. Chondroitin sulfate can bind with
core protein to produce highly absorbent aggregan, which is a
major structure inside cartilage and acts as a shock absorber,
or it can produce sydecan, which is a cell receptor which can
interact with adhesion proteins, cells and the extracellular ma-
trix (ECM) [233]. In vitro studies suggest that chondroitin
sulfate is also able to increase matrix component production by
human chondrocytes [234]. Furthermore, chondroitin sulfate
proteoglycans have a critical role in regeneration and plasticity
in the central nervous system as reviewed by Galtrey and
Fawcett [235].
However, the readily water-soluble nature of chondroitin
sulfate limits its application as a solid-state drug delivery
vehicle. Therefore, it is usual to carry out a crosslinking treat-
ment to tailor the properties of chondroitin sulfate as reported inTable 9
Chondroitin sulfate-based matrices/scaffolds for drug and cell delivery used in diffe
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule





Chondroitin sulfate–chitosan sponges Bone PDGF-BB
Chondroitin sulfate–collagen–chitosan
freeze-dried scaffolds with chitosan
microspheres
Cartilage TGF-β1













Chondroitin sulfate–collagen scaffolds Cartilage –
Chondroitin sulfate–collagen hydrogels Heart valve –
Chondroitin sulfate–PVA hydrogels Kidney –
Abbreviations: bFGF: basic fibroblast growth factor; rhBMP-2: recombinant human b
vascular endothelial growth factor; PDGF-BB: Platelet-derived growth factor-BB; PV
mitral valve interstitial cells (VICs) and endothelial cells (VECs);
Compiled from references [148,223,233,238–247].several works [233,236,237] or to combine it with other poly-
mers, such as chitosan [238], gelatin and hyaluronan [239,240],
collagen [241,242], poly(vinyl alcohol) [233] or poly-(lactic-
co-glycolic acid) [240] in order to produce more stable mate-
rials. Moreover, and since chondroitin sulfate in negatively
charged, interaction with positively charged molecules such as
polymers or growth factors is anticipated being a key issue to
facilitate the design of delivery systems. For instances this
characteristic is used to produce chondroitin sulfate–chitosan
sponges as delivery systems for platelet-derived growth factor-
BB (PDGF-BB) for bone regeneration as reported by Jeong
Park et al. [238] where this interaction shown to induce more
prolonged release of the growth factor. As previously referred,
due to its biocharacteristics, chondroitin sulfate has been used in
some extent in the tissue engineering field, mainly in cartilage
applications. The aim of the following in Table 9 is to show the
diversified applications (besides cartilage) of this natural
occurring polymer as carrier for growth factor or cell delivery
in this field.
An interesting approach using chondroitin sulfate is pro-
posed by Daamen et al. [245] by reporting the preparation of
molecularly-defined collagen–elastin–glycosaminoglycan scaf-
folds. Given the large heterogeneity in the body's scaffolds, it is
the purpose of this study to demonstrate that tailor-made,
molecularly-defined scaffolds can be produced from the main
components of the extracellular matrix using in this case highly
purified collagen, elastin, and chondroitin sulfate in order to
produce organ-specific scaffolds for tissue engineering. The





– Rat hind limbs [242]
Rat calvarial cells – [238]
Rabbit articular chondrocytes – [148]
Porcine vascular endothelial cells – [244]















Bovine articular chondrocytes – [247]




one morphogenetic protein-2; TGF-β1: transforming growth factor-β1; VEGF:
A: poly(vinyl alcohol); PLGA: poly-(lactic-co-glycolic acid); VICs and VECs:
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elastin (which is crucial for instances in blood vessels) and the
bind capacity to growth-active molecules of chondroitin sulfate.
This interesting approach is also one example of the effort that
has to be done in trying to reduce the variability generally found
of natural–origin polymers by using highly purified and charac-
terized polymers producing molecularly-defined scaffolds.
In terms of commercially availability, chondroitin sulfate is
widely marketed in USA and Europe as a nutritional supple-
ment together with glucosamine used in the treatment of
osteoarthritic patients. Chondroitin sulfate is also a component
of the dermal layer of the FDA-approved skin substitute for
treating burns [233]. An available commercial product is In-
tegra® Dermal Regeneration Template marketed by Integra in
USAwhich a bilayered membrane system for skin replacement
that provides a scaffold for dermal regeneration. The dermal
replacement layer is made of a porous matrix of fibers of
crosslinked bovine tendon collagen and a glycosaminoglycan
(chondroitin-6-sulfate) manufactured with a controlled porosity
and defined degradation rate. According to the manufacturer,
Integra® Dermal Regeneration Template is the first and only
FDA-approved tissue engineered product for burn and recon-
structive surgery. As hyaluronan, chondroitin sulfate is also used
as a surgical aid in anterior segment procedures including
cataract extraction and intraocular lens implantation. An exam-
ple is Viscoat® from Alcon Laboratories in UK which is a
solution of 4% chondroitin sulfate and 3% sodium hyaluronate.
3.7. Other polysaccharidic polymers
Other polysaccharides have been studied for tissue engi-
neering applications. Some of them, the so-called cold set gels
which form a gel on cooling the solution [124] like agarose,
carrageenans and gellan gum have been studied in some extent
the frame of drug delivery for tissue engineering and are de-
scribed as follows. Due to their still narrow applications (but
potential) as the drug delivery carriers in the tissue engineering
field, the authors have chosen to overview them together in this
section.
Dextran is a branched, high molecular weight polymer of D-
glucose, produced by different bacterial strains from sucrose via
the action of dextransucrase enzyme [248], consisting of
α(1→6)-linked D-glucose residues with some degree of branch-
ing via α(1→3) linkages. Dextran is readily available in a wide
range of molecular weights along with several derivatives and it
is biodegradable and biocompatible. These properties make it
suitable for a whole range of applications, such as plasma-
expanders and blood substitutes, since it binds to erythrocytes,
platelets and vascular endothelium by reducing their aggrega-
tion and adhesiveness, respectively. Additionally, it has also
been shown to be a bone healing promoter and also for dermal
and subcutaneous augmentation and for drug delivery [125].
Agar, the native polysaccharide of agarose, forms thermo-
reversible gels when dissolved in water. It consists of two main
components, agarose and agaropectin. Agarose is a linear poly-
saccharide consisting on (1→3)-β-D-galactopyranose-(1→4)-
3,6-anhydro-α-L-galactopyranose as the basic unit and containsa few ionized sulfate groups [249]. Agarose is normally insol-
uble in organic solvents and cannot form gels. Apparently the
gelling possibility in aqueous solutions is a consequence of the
structure of water. The arrangement of the agarose chains that
join together and adopt a double helix so tight that any gaps are
closed, trapping any water inside the helix [249]. These double
stranded helices are the result of specific intermolecular hydro-
gen bonding that contributes to the rigidity of the polymer
chains [249]. Adding hydrogen bond decomposing agents like
urea can have a tremendously negative effect on the gelling
properties. Gelation occurs at temperatures below 40 °C, where-
as the melting temperature appears to be 90 °C [250]. The
viscoelastic properties of aqueous agarose gels depend strongly
on the degree of desulfation of its native polysaccharide agar:
the propensity to form gels increases with increasing desulfation
[250].
Carrageenans are a family of sulfated polysaccharides
extracted from red marine algae and that are widely utilized in
the industry because they can form reasonably stiff and thermo-
reversible gels in the presence of so-called gel-promoting salts
at room temperature [251]. These polysaccharides are linear
polymers consisting of chains of (1→3)-linked β-D-galactose
and (1→4)-linked α-D-galactose units which are variously
substituted and modified to the 3,6-anhydro derivative, depend-
ing on the source and extraction conditions [113]. Three major
types of carrageenan are recognized on the basis of their pat-
terns of sulfate esterification: κ (kappa), ι (iota), and λ
(lambda). All carrageenans are highly flexible molecules,
which, at higher concentrations, wind around each other to
form double-helical structures. A particular advantage is that
they are thixotropic [252], i.e., they thin under shear stress and
recover their viscosity once the stress is removed. Due to the
strong ionic nature, these carrageenans exhibit a high degree of
protein reactivity. These materials have been used in the field of
drug delivery [253–255], which creates the potential for their
use as drug delivery systems in tissue engineering. Carragee-
nans have been used mainly in the food industry, and several
companies commercialize it — FMC BioPolymer or Carra-
geenan Company. Genialab in Germany is marketing genia-
Beads® CG which are hydrogel beads made from carrageenan.
Gellan gum is a high molecular weight microbial exopoly-
saccharide produced by Pseudomonas elodea. It is a linear
anionic heteropolysaccharide composed of the tetrasaccharide
(1→4)-L-rhamnose-α(1→3)-D-glucose-β(1→4)-D-glucuronic
acid-β(1→4)-D-glucose as repeating unit, with carboxylic side
groups. Gellan gum is widely used in the food industry thanks
to its ability to form transparent gels resistant to heat and acid in
comparison to other polysaccharide gels. In its native or high
acyl form, two acyl substituents D-acetate and D-glycerate are
present. Both substituents are located in the same glucose resi-
due. The high acyl form produces transparent, soft, elastic and
flexible gels which are resistant to heat and acid, whereas the
low acyl form produces firm, non-elastic brittle [125]. Gel
formation is due to a conformational heat-reversible transition
from a state of single random macromolecules to a more ordered
state where macromolecules pair with each other to form double
helixes [125]. A single macromolecule can be involved in the
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the helixes are formed and consequently a gel is obtained [125].
Gellan gum has been studied for drug delivery applications,
both as adjuvants [256] and as vehicle for drug delivery [257].
Its use for tissue engineering applications is taking the first
steps, documented in Suri and Banerjee [258], where the au-
thors have used a gellan gum gel as a substitute for the vitreous
of the eye, and its properties were comparable to the commonly
used material (silicone). Commercially available gellan gum,
Gelrite®, a novel ophthalmic vehicle, gels in the presence of
mono- or divalent-cations present in the lacrimal fluid. It effi-
cacy was comparable to marketed eye drops in efficacy of
treatment of bacterial conjunctivitis that was induced artificially
in rabbits [259]. Its properties, similar to other materials already
studied in the tissue engineering field, make this material a
suitable candidate for both cell encapsulation and drug delivery
applications.
Cellulose is often referred as the most abundant organic
polymer in the world [260] and therefore it is readily available
and has a low cost. The ease in which it can be converted to
derivatives makes it an attractive raw material [124]. In nature,
it is the primary structural component of plant cell walls [261].
This is a linear polysaccharide of D-glucose units linked by
β(1→4) glycosidic bonds [261,262] where every other glucose
residue is rotated approximately 180° [262]. As a result, cello-
biose is the structural repeating unit of the glucan chains in
cellulose [262]. The glucan chains in cellulose are parallel to
each other and are packed side by side to form microfibrils,
which stabilizes the structure, minimizing its flexibility [263].Table 10
Polysaccharides-based matrices/scaffolds for drug, cell and gene delivery used in di
Polymer(s)/carrier/
scaffold structure
TE application Active biomolecule
Dextran beads












Agarose film Cartilage FGF-2
Agarose gel Bone/cartilage BMP-2 gene
Agarose sponge Pancreas Insulin
Agarose gel Intervertebral disc TGF-β1
Agarose gel Cartilage –
Agarose–fibrin gel Cornea –
Gellan gum (Gelrite®) Ophthalmology Antibiotic
Gellan gum hydrogel Eye (vitreous) –
Cellulose hollow-fibers Not defined Fibronectin
Cellulose porous scaffold Cartilage –
Abbreviations: rhBMP-2: recombinant human bone morphogenetic protein-2; IGF-1
factor-2; BMP-2: bone morphogenetic protein-2; TGF-β1: transforming growth fact
Compiled from references [21,29,30,101,200,212,258,259,270–277].This highly cohesive, hydrogen-bonded structure, gives cellu-
lose fibers exceptional strength and makes them water insoluble
despite their hydrophilicity [263]. Cellulosic materials exhibit,
however, poor degradation in vivo [264]. A cellulose sponge
has been evaluated in rats' femurs for its permissibility for bone
formation and it was found to need more time to regenerate than
the control [265]. However, with growth factors' supplemen-
tation, this material can further display a desirable enhancement
of bone formation. Several works have investigated the use of
cellulose for cartilage [266,267], bone [268,269] and cardiac
[264] applications. Hydroxypropylcellulose is a non-ionic
water-soluble cellulose ether with a remarkable combination
of properties. It combines organic-solvent solubility, thermo-
plasticity and surface activity. The molecular weight is varied
by controlling the degree of polymerization of the cellulose
backbone, which, in turn, controls the viscosity of hydro-
xypropylcellulose; as the degree of polymerization increases,
the viscosity of the polymer increases. Hydroxypropylcellulose
is used in pharmaceutical formulations for various purposes:
low-viscosity grades are used as tablet binders in immediate-
release dosage forms and medium- and high-viscosity grades
are used in sustained-release matrix formulations. Hydro-
xyethylcellulose is a nonionic water-soluble polymer derived
from cellulose. There is a commercially available hydroxyethyl-
cellulose named Natrosol® 250HX distributed by Hercules in
USA and has a degree of substitution of 1.5 (three hydroxyls
substituted/two units). Genialab in Germany is also marketing
geniaBeads® MC which are hydrogel beads made from modi-




– Dog class III
furcation defect
[270]
– Periodontal defect [271]




Periostal explants Rabbit knee [200]
Bone marrow
stromal cells (transfected)




Human intervertebral disc cells – [29,30,212]














: insulin growth factor-I; ECM: extracellular matrix; FGF-2: fibroblast growth
or-β1.
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the previously described polysaccharidic polymers as matrices
or scaffolds in the tissue engineering field.
4. Polyhydroxyalkanoates
In nature, a special group of polyesters is produced by a wide
variety of microorganisms as an internal carbon and energy
storage, as part of their survival mechanism [278]. Poly(β-
hydroxybutyrate) (PHB) was first mentioned in the scientific
literature as early as 1901 [1]. Bacterially synthesized poly-
hydoxyalkanoates (PHAs) have attract much attention because
they can be produced from a variety of renewable resources, and
are truly biodegradable and highly biocompatible thermoplastic
materials [1]. Although a great variety of materials of this
family can be produced, the use of PHAs in tissue engineering
has been mainly restricted to PHBs and poly(hydroxybutyrate-
co-valerate) (PHBV) [279,280]. The brittleness of PHB was
improved through copolymerization of β-hydroxybutyrate with
β-hydroxyvalerate [281], which was first commercialized in
1990, but the high price of PHBV is still the major barrier to its
wide spread usage [1]. The copolymerization produces less
crystalline, more flexible and more readily processable mate-
rials than pure PHB. Depending on the requirements of different
applications, PHA can be either blended, surface modified or
combined with other polymers, enzymes or even inorganic
materials, such as hydroxylapatite, to further adjust their me-
chanical properties or biocompatibility [279]. Interesting phys-
ical properties of polyhydroalkanoates include nonlinear optical
activity and piezoelectricity [282], i.e. the capacity of a material
to suffer electric polarization due to mechanical stress. Such
properties can be very useful to tailor the material in question,
increasing further promise applications of these polymers in
areas such as tissue engineering and drug delivery. Neverthe-
less, polyhydroxybutyrates have already been studied to some
extent for tissue engineering applications [279], mainly for
scaffold materials in combination with ceramic materials [283–
285], as a vehicle for drug delivery [286,287] and also as a
material for cardiac tissue engineering [288].
Commercially available PHBs (poly-β-hydroxybutyrate
homopolymer) BIOPOLGO4 is commercialized by IC1
Biological Products in the form of compression-molded sheets
0.5 mm thick. Similarly, ICI commercialized BIOPOLP05, the
co-polymer poly(β-hydroxybutyrate-co-β-hydroxyvalerate)
containing 24% hydroxyvalerate.
5. Final remarks and future directions
Natural origin polymers have received considerable interest
for drug delivery and tissue engineering applications. However,
the combination of both applications into a single material has
proven to be very challenging. This paper reviews the properties
of natural–origin materials that render them attractive for
applications where the combination of a scaffold material and a
carrier for an active biomolecules is desirable. We also review
research works were this combination of properties has been
described, and summarize them in comprehensive tables foreach polymer. The described systems include mainly growth
factors delivery or cell carriers with application in the tissue
engineering field targeting, as described, a range of biological
living tissues. The most relevant properties for the aimed
applications of the natural–origin polymers were described with
a special focus in the description of protein-based polymers and
polysaccharides due to their similarity with the extracellular
matrix. The use of porous scaffolds, microparticles, membranes,
hydrogels and injectable systems from such kind of materials is
also focused, especially on what concerns to the present status
of the research in this field that should lead towards their final
application. Some examples of commercially available natural–
origin polymers or systems that can find use in research or in the
clinical were also identified and described. Moreover, the bio-
logical performance of the described systems based on natural-
based polymers is presented, based on several examples aiming
at different clinical-relevant applications.
Although natural origin materials present some drawbacks
namely the difficulties in controlling the variability from batch
to batch, mechanical properties or limited processability, their
advantages clearly surplus the drawbacks. Their degradability,
biocompatibility, low cost and availability, similarity with the
extracellular matrix and intrinsic cellular interaction makes
them attractive very candidates for biomedical applications, in
particular as drug delivery systems for tissue engineering appli-
cations as described in this paper.
The aforementioned drawbacks are obviously limiting the
widespread use of natural–origin polymers, mainly in clinical
purposes. To try to overcome this disadvantage and for rational
design of carriers/scaffolds for tissue engineering, it is essential
to study the effect of individual components. To do so, tem-
plates have to be designed starting with highly purified mole-
cules and the contribution of each component in the scaffold has
to be controlled. Furthermore, when biomolecules such as
growth factors are incorporated a further insightful study is
needed in terms of interactions. Molecular design of these
materials has clearly an important role in determining their
suitability in such applications. Emerging technologies such as
recombinant protein technologies and the development of
molecularly-defined polymers can hinder this, by producing
the polymer in a controlled, reliable and reproducible approach.
A described example is the use of elastin-derived polypeptides
or molecularly-defined polymers. Therefore, a better controlled
development in methods for production, purification, or in
material properties such as molecular weight, mechanical be-
havior or degradation rate is essential to widespread the use of
these class of polymers.
In this paper, the authors have also presented some few
examples of commercially available natural–origin products.
However it is in some way limited because the availability of
products with clinical relevance is still very narrowed especially
if we limited the application to drug delivery field for tissue
engineering applications. It is our conviction that a great deal of
research work is still needed in order to obtain an increased
number of commercially available and clinically successful
natural-based systems and that emerging knowledge and tech-
nology is leading to a noteworthy exponential growth in this
226 P.B. Malafaya et al. / Advanced Drug Delivery Reviews 59 (2007) 207–233area. Undoubtedly, natural–origin polymers or nature-inspired
materials appear as the natural and desired choice for the re-
ferred applications.
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